Targeted protein degradation is getting explored instead strategy in cancer, whereby the purely natural protein degradation procedure is co-opted for therapeutic functions. Lately developed novel molecules termed proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. One particular ligand binds on the ‘protein of curiosity’ (POI) https://www.directivepublications.org/journal-of-clinical-breast-cancer/